XML 49 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
Product Revenues, Net (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Valuation and Qualifying Accounts Disclosure [Line Items]    
Customer deposits $ 147,686 $ 73,416
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 89,201  
Provision related to current period sales 92,611  
Adjustments related to prior period sales (3,655)  
Credits/payments made (77,401)  
Balance at June 30, 2017 100,756  
Trade Allowances    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 2,568  
Provision related to current period sales 11,941  
Adjustments related to prior period sales (194)  
Credits/payments made (11,683)  
Balance at June 30, 2017 2,632  
Rebates, Chargebacks and Discounts    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 81,927  
Provision related to current period sales 69,669  
Adjustments related to prior period sales (3,268)  
Credits/payments made (58,121)  
Balance at June 30, 2017 90,207  
Product Returns    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 3,492  
Provision related to current period sales 1,777  
Adjustments related to prior period sales (48)  
Credits/payments made (631)  
Balance at June 30, 2017 4,590  
Other Incentives    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 1,214  
Provision related to current period sales 9,224  
Adjustments related to prior period sales (145)  
Credits/payments made (6,966)  
Balance at June 30, 2017 3,327  
Cystic Fibrosis Foundation Therapeutics Incorporated    
Valuation and Qualifying Accounts Disclosure [Line Items]    
Customer deposits $ 147,700